Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

A Pan-cancer Analysis to Determine the Prognostic Analysis and Immune Infiltration of HSPA5

Author(s): Rong-Kun Zhu, Wei Zhang, Yi-Xing Zhang, Zeng hui and Xiong-Wei Wang*

Volume 24, Issue 1, 2024

Published on: 31 May, 2023

Page: [14 - 27] Pages: 14

DOI: 10.2174/1568009623666230508111721

Price: $65

conference banner
Abstract

Background: Heat shock 70kDa protein 5 (HSPA5), also known as GRP78, is widely expressed in most malignant cells and has been shown to have a significant role in the spread of most malignancies by transferring them to the cell membrane. High-level HSPA5 may serve as an independent prognostic marker for various malignancies due to its ability to accelerate tumor growth and migration, inhibit cell apoptosis and closely connect to prognosis. Therefore, it is crucial to examine HSPA5 using pan-cancer research, which might result in the discovery of novel cancer treatment targets.

Methods: The GTEx and TCGA databases have both provided evidence of the expression of various amounts of HSPA5 in various tissues. The Clinical Proteomics Tumor Analysis Consortium (CPTAC) evaluated the levels of HSPA5 protein expression, while qPCR investigations also evaluated the expression of HSPA5 mRNA in certain tumors. HSPA5 was studied using the Kaplan-Meier method to examine how it influences overall survival and disease-free survival in malignancies. GEPIA2 was used to investigate the correlation between HSPA5 expression and the clinical stage of cancer. The tumor-immune system interaction database (TISIDB) examined the expression of HSPA5 in association with molecular and tumor immune subtypes. The co-expressed genes of HSPA5 were extracted from the STRING database, and the top 5 co-expressed genes of HSPA5 in 33 cancers were identified using the TIMER database. Further research examined the relationship between tumor mutations and HSPA5. Microsatellite Instability (MSI) and Tumor Mutation Burden (TMB) were the primary areas of interest. The association between HSPA5 mRNA expression and immune infiltration was also explored using the TIMER database. Additionally, through the Linkedomics database, we examined the enrichment of GO and KEGG for HSPA5 in glioblastoma. Finally, the Cluster Analyzer tool was used to carry out a GSEA functional enrichment investigation.

Results: HSPA5 mRNA expression was found to be greater in all 23 tumor tissues than in the equivalent normal tissues, and high HSPA5 expression appeared to be strongly related to a poor prognosis in the majority of cancers, as observed by survival plots. In the tumour clinical stage display map, HSPA5 showed differential expression in most tumours. HSPA5 is strongly associated with Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI). Cancer-associated Fibroblasts (CAFs) infiltration was strongly associated with HSPA5, as were nine immunological subtypes of malignancy and seven molecular subtypes of malignancy. According to the results of GO and KEGG enrichment analyses, HSPA5 in GBM is mostly involved in neutrophil-mediated immunological and collagen metabolic activities. Additionally, GSEA enrichment analyses of HSPA5 and associated genes demonstrated a substantial link between HSPA5 and the immunological milieu of tumors, cell division and nervous system regulation. By using qPCR, we were able to further corroborate the enhanced expression in the GBM, COAD, LUAD and CESC cell lines.

Conclusion: Our bioinformatics research leads us to hypothesize that HSPA5 may be involved in immune infiltration as well as tumor growth and progression. Additionally, it was found that differentially expressed HSPA5 is linked to a poor prognosis for cancer, with the neurological system, the tumor immunological microenvironment and cytokinesis being potential contributing factors. As a result, HSPA5 mRNA and the associated protein might be used as therapeutic targets and possible prognostic markers for a range of malignancies.

Keywords: Heat shock 70kDa protein 5(HSPA5), cancer-associated fibroblasts, immune infiltration, microsatellite instability, tumor mutation burden, cytokinesis.

« Previous Next »
Graphical Abstract

[1]
Wisniewska, M.; Karlberg, T.; Lehtiö, L.; Johansson, I.; Kotenyova, T.; Moche, M.; Schüler, H. Crystal structures of the ATPase domains of four human Hsp70 isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B′ and HSPA5/BiP/GRP78. PLoS One, 2010, 5(1), e8625.
[http://dx.doi.org/10.1371/journal.pone.0008625] [PMID: 20072699]
[2]
Hernandez, I.; Cohen, M. Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies. Cancer Lett., 2022, 524, 1-14.
[http://dx.doi.org/10.1016/j.canlet.2021.10.004] [PMID: 34637844]
[3]
Farshbaf, M.; Khosroushahi, A.Y.; Mojarad-Jabali, S.; Zarebkohan, A.; Valizadeh, H.; Walker, P.R. Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer. J. Control. Release, 2020, 328, 932-941.
[http://dx.doi.org/10.1016/j.jconrel.2020.10.055] [PMID: 33129921]
[4]
Zhang, L.H.; Zhang, X. Roles of GRP78 in physiology and cancer. J. Cell. Biochem., 2010, 110(6), 1299-1305.
[http://dx.doi.org/10.1002/jcb.22679] [PMID: 20506407]
[5]
Gopal, U.; Mowery, Y.; Young, K.; Pizzo, S.V. Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling. J. Biol. Chem., 2019, 294(38), 13939-13952.
[http://dx.doi.org/10.1074/jbc.RA119.009091] [PMID: 31358620]
[6]
Gopal, U.; Pizzo, S.V. Cell surface GRP78 signaling: An emerging role as a transcriptional modulator in cancer. J. Cell. Physiol., 2021, 236(4), 2352-2363.
[http://dx.doi.org/10.1002/jcp.30030] [PMID: 32864780]
[7]
Fu, R.; Yang, P.; Wu, H.L.; Li, Z.W.; Li, Z.Y. GRP78 secreted by colon cancer cells facilitates cell proliferation via PI3K/Akt signaling. Asian Pac. J. Cancer Prev., 2014, 15(17), 7245-7249.
[http://dx.doi.org/10.7314/APJCP.2014.15.17.7245] [PMID: 25227822]
[8]
Moradi-Marjaneh, R.; Paseban, M.; Moradi Marjaneh, M. Hsp70 inhibitors: Implications for the treatment of colorectal cancer. IUBMB Life, 2019, 71(12), 1834-1845.
[http://dx.doi.org/10.1002/iub.2157] [PMID: 31441584]
[9]
Suyama, K.; Watanabe, M.; Sakabe, K.; Otomo, A.; Okada, Y.; Terayama, H.; Imai, T.; Mochida, J. GRP78 suppresses lipid peroxidation and promotes cellular antioxidant levels in glial cells following hydrogen peroxide exposure. PLoS One, 2014, 9(1), e86951.
[http://dx.doi.org/10.1371/journal.pone.0086951] [PMID: 24475200]
[10]
Markouli, M.; Strepkos, D.; Papavassiliou, A.G.; Piperi, C. Targeting of Endoplasmic Reticulum (ER) stress in gliomas. Pharmacol. Res., 2020, 157, 104823.
[http://dx.doi.org/10.1016/j.phrs.2020.104823] [PMID: 32305494]
[11]
Xia, S.; Duan, W.; Liu, W.; Zhang, X.; Wang, Q. GRP78 in lung cancer. J. Transl. Med., 2021, 19(1), 118.
[http://dx.doi.org/10.1186/s12967-021-02786-6] [PMID: 33743739]
[12]
Ninkovic, S.; Harrison, S.J.; Quach, H. Glucose-Regulated Protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma. Expert Rev. Hematol., 2020, 13(11), 1201-1210.
[http://dx.doi.org/10.1080/17474086.2020.1830372] [PMID: 32990063]
[13]
Chen, H.A.; Chang, Y.W.; Tseng, C.F.; Chiu, C.F.; Hong, C.C.; Wang, W.; Wang, M.Y.; Hsiao, M.; Ma, J.T.; Chen, C.H.; Jiang, S.S.; Wu, C.H.; Hung, M.C.; Huang, M.T.; Su, J.L. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer. Ann. Surg. Oncol., 2015, 22(3), 889-898.
[http://dx.doi.org/10.1245/s10434-014-4061-3] [PMID: 25212833]
[14]
Teng, Y.; Ai, Z.; Wang, Y.; Wang, J.; Luo, L. Proteomic identification of PKM2 and HSPA5 as potential biomarkers for predicting high-risk endometrial carcinoma. J. Obstet. Gynaecol. Res., 2013, 39(1), 317-325.
[http://dx.doi.org/10.1111/j.1447-0756.2012.01970.x] [PMID: 22889453]
[15]
Hamada, M.; Inaba, H.; Nishiyama, K.; Yoshida, S.; Yura, Y.; Matsumoto-Nakano, M.; Uzawa, N. Prognostic association of starvation-induced gene expression in head and neck cancer. Sci. Rep., 2021, 11(1), 19130.
[http://dx.doi.org/10.1038/s41598-021-98544-1] [PMID: 34580365]
[16]
Niu, Z.; Wang, M.; Zhou, L.; Yao, L.; Liao, Q.; Zhao, Y. Elevated GRP78 expression is associated with poor prognosis in patients with pancreatic cancer. Sci. Rep., 2015, 5(1), 16067.
[http://dx.doi.org/10.1038/srep16067] [PMID: 26530532]
[17]
Wen, X.; Chen, X.; Chen, X. Increased expression of GRP78 correlates with adverse outcome in recurrent glioblastoma multiforme patients. Turk Neurosurg., 2020, 30(1), 11-16.
[PMID: 30649790]
[18]
Zheng, H.; Takahashi, H.; Li, X.; Hara, T.; Masuda, S.; Guan, Y.; Takano, Y. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum. Pathol., 2008, 39(7), 1042-1049.
[http://dx.doi.org/10.1016/j.humpath.2007.11.009] [PMID: 18482745]
[19]
Rui, L.; Gu, Y.; He, W.; Wang, Y.; Huang, J.; Zheng, H.; Su, R.; Luan, Z. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells. Oncotarget, 2017, 8(12), 19354-19364.
[20]
Bailly, C.; Waring, M.J. Pharmacological effectors of GRP78 chaperone in cancers. Biochem. Pharmacol., 2019, 163, 269-278.
[http://dx.doi.org/10.1016/j.bcp.2019.02.038] [PMID: 30831072]
[21]
Uckun, F.M.; Qazi, S.; Ozer, Z.; Garner, A.L.; Pitt, J.; Ma, H.; Janda, K.D. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. Br. J. Haematol., 2011, 153(6), 741-752.
[http://dx.doi.org/10.1111/j.1365-2141.2011.08671.x] [PMID: 21517817]
[22]
Rosati, E.; Sabatini, R.; Rampino, G.; De Falco, F.; Di Ianni, M.; Falzetti, F.; Fettucciari, K.; Bartoli, A.; Screpanti, I.; Marconi, P. Novel targets for endoplasmic reticulum stress-induced apoptosis in B-CLL. Blood, 2010, 116(15), 2713-2723.
[http://dx.doi.org/10.1182/blood-2010-03-275628] [PMID: 20628148]
[23]
Roué, G.; Pérez-Galán, P.; Mozos, A.; López-Guerra, M.; Xargay-Torrent, S.; Rosich, L.; Saborit-Villarroya, I.; Normant, E.; Campo, E.; Colomer, D. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood, 2011, 117(4), 1270-1279.
[http://dx.doi.org/10.1182/blood-2010-04-278853] [PMID: 21106982]
[24]
Rich, J.T.; Neely, J.G.; Paniello, R.C.; Voelker, C.C.J.; Nussenbaum, B.; Wang, E.W. A practical guide to understanding Kaplan‐Meier curves. Otolaryngol. Head Neck Surg., 2010, 143(3), 331-336.
[http://dx.doi.org/10.1016/j.otohns.2010.05.007] [PMID: 20723767]
[25]
Hess, A.S.; Hess, J.R. Kaplan–Meier survival curves. Transfusion, 2020, 60(4), 670-672.
[http://dx.doi.org/10.1111/trf.15725] [PMID: 32077507]
[26]
Li, Q.; Pan, Y.; Cao, Z.; Zhao, S. Comprehensive analysis of prognostic value and immune infiltration of chromobox family members in colorectal cancer. Front. Oncol., 2020, 10, 582667.
[http://dx.doi.org/10.3389/fonc.2020.582667] [PMID: 33014884]
[27]
Ru, B.; Wong, C.N.; Tong, Y.; Zhong, J.Y.; Zhong, S.S.W.; Wu, W.C.; Chu, K.C.; Wong, C.Y.; Lau, C.Y.; Chen, I.; Chan, N.W.; Zhang, J. TISIDB: An integrated repository portal for tumor-immune system interactions. Bioinformatics, 2019, 35(20), 4200-4202.
[http://dx.doi.org/10.1093/bioinformatics/btz210] [PMID: 30903160]
[28]
Li, T.; Fan, J.; Wang, B.; Traugh, N.; Chen, Q.; Liu, J.S.; Li, B.; Liu, X.S. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res., 2017, 77(21), e108-e110.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-0307] [PMID: 29092952]
[29]
Mering, C.; Huynen, M.; Jaeggi, D.; Schmidt, S.; Bork, P.; Snel, B. STRING: A database of predicted functional associations between proteins. Nucleic Acids Res., 2003, 31(1), 258-261.
[http://dx.doi.org/10.1093/nar/gkg034] [PMID: 12519996]
[30]
Vasaikar, S.V.; Straub, P.; Wang, J.; Zhang, B. LinkedOmics: Analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res., 2018, 46(D1), D956-D963.
[http://dx.doi.org/10.1093/nar/gkx1090] [PMID: 29136207]
[31]
Zhang, Y.; Zhang, Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell. Mol. Immunol., 2020, 17(8), 807-821.
[http://dx.doi.org/10.1038/s41423-020-0488-6] [PMID: 32612154]
[32]
Mao, X.; Xu, J.; Wang, W.; Liang, C.; Hua, J.; Liu, J.; Zhang, B.; Meng, Q.; Yu, X.; Shi, S. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol. Cancer, 2021, 20(1), 131.
[http://dx.doi.org/10.1186/s12943-021-01428-1] [PMID: 34635121]
[33]
Asif, P.J.; Longobardi, C.; Hahne, M.; Medema, J.P. The role of cancer-associated fibroblasts in cancer invasion and metastasis. Cancers (Basel), 2021, 13(18), 4720.
[http://dx.doi.org/10.3390/cancers13184720] [PMID: 34572947]
[34]
Jenifer, B.G.; Reginald, H. GRP78 influences chemoresistance and prognosis in Cancer. Curr. Drug Targets, 2017, 19(6), 701-708.
[35]
Karali, E.; Bellou, S.; Stellas, D.; Klinakis, A.; Murphy, C.; Fotsis, T. VEGF Signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. Mol. Cell, 2014, 54(4), 559-572.
[http://dx.doi.org/10.1016/j.molcel.2014.03.022] [PMID: 24746698]
[36]
Nagelkerke, A.; Bussink, J.; Sweep, F.C.; Span, P.N. The unfolded protein response as a target for cancer therapy. Biochim. Biophys. Acta, 2014, 1846(2), 277-284.
[PMID: 25069067]
[37]
Misra, U.K.; Kaczowka, S.; Pizzo, S.V. Inhibition of NF-κB1 and NF-κB2 activation in prostate cancer cells treated with antibody against the carboxyl terminal domain of GRP78: Effect of p53 upregulation. Biochem. Biophys. Res. Commun., 2010, 392(4), 538-542.
[http://dx.doi.org/10.1016/j.bbrc.2010.01.058] [PMID: 20097177]
[38]
Yao, X.; Liu, H.; Zhang, X.; Zhang, L.; Li, X.; Wang, C.; Sun, S. Cell surface GRP78 accelerated breast cancer cell proliferation and migration by activating STAT3. PLoS One, 2015, 10(5), e0125634.
[http://dx.doi.org/10.1371/journal.pone.0125634] [PMID: 25973748]
[39]
Dang, C.V.; O’Donnell, K.A.; Zeller, K.I.; Nguyen, T.; Osthus, R.C.; Li, F. The c-Myc target gene network. Semin. Cancer Biol., 2006, 16(4), 253-264.
[http://dx.doi.org/10.1016/j.semcancer.2006.07.014] [PMID: 16904903]

Rights & Permissions Print Cite
Article Metrics
35
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy